Lin F, Liu S, Ren J, Wei J, Xu S, Liu R, Yao E
Hematology Research Laboratory, Second Affiliated Hospital, Hebei Medical University, Shijiazhung.
J Tongji Med Univ. 1996;16(2):75-7. doi: 10.1007/BF02887961.
The flow cytometric immunoassay was used to study the correlation between the H-ras oncogene product p21 and the DNA ploidy in 30 de novo cases of acute myelogenous leukemia (AML). The results showed that 17 cases were negative for p21 expression and 13 positive for p21. The patients with positive p21 had higher percentage of bone marrow and peripheral blasts and lower peripheral leukocyte count. The expression of p21 had no influence on the therapeutic effect. Before treatment, DNA diploidy occurred in 18 cases including 13 p21 negative ones, and DNA aneuploidy was revealed in 12 cases including 8 p21 positive ones. Patients with positive p21 or having aneuploidy in complete remission were at risk for early relapse. Our results suggest that p21 may be involved in the process of leukemogenesis and progression in AML.
采用流式细胞术免疫分析法研究了30例初发急性髓细胞白血病（AML）患者中H-ras癌基因产物p21与DNA倍体之间的相关性。结果显示，17例p21表达阴性，13例p21表达阳性。p21阳性患者的骨髓和外周血原始细胞百分比更高，外周血白细胞计数更低。p21的表达对治疗效果无影响。治疗前，18例出现DNA二倍体，其中13例p21阴性；12例出现DNA非整倍体，其中8例p21阳性。p21阳性或完全缓解时存在非整倍体的患者有早期复发风险。我们的结果表明，p21可能参与了AML的白血病发生和进展过程。
